Details of Disease

General Information of Disease (ID: DIS3F9EY)

• Disease Name: Skin and skin-structure infection
• Disease Class: 1F28-1G0Z: Skin and skin-structure infection
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS3F9EY: Skin and skin-structure infection
• ICD Code: ICD-11: ICD-11: 1F28-1G0Z
• Disease Identifiers:
  MONDO ID: MONDO_0021201
  MESH ID: D012874
  UMLS CUI: C0037278
  MedGen ID: 52365
  SNOMED CT ID: 108365000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cefilavancin	DMDMJ9O	Phase 3	Small molecular drug	[1]
Ceftobiprole	DMM76GL	Phase 3	Small molecular drug	[2]
Ceftobiprole medocaril	DMWLF2X	Phase 3	Small molecular drug	[3]
BC-7013	DMMKCJ6	Phase 2	NA	[4]
TNP-2092	DM8DZKI	Phase 2	Small molecular drug	[5]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
GALNS	TTT9YPO	Strong	Biomarker	[6]
IDE	TT2EDHU	Strong	Biomarker	[7]
LCT	TTA0OSE	Strong	Biomarker	[8]
TST	TT51OTS	Strong	Biomarker	[9]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC9A6	DTN0JXW	Limited	Biomarker	[10]

This Disease Is Related to 12 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADSS2	OTW26XXB	Strong	Biomarker	[11]
AGBL2	OTCX9987	Strong	Biomarker	[12]
CD177	OTS79FNF	Strong	Biomarker	[13]
DOCK8	OTNQLL21	Strong	Biomarker	[14]
FAM3B	OTC2S91N	Strong	Biomarker	[15]
FLG	OTE9QDV6	Strong	Genetic Variation	[16]
MYO9B	OTQ94R5K	Strong	Biomarker	[17]
NBEAL1	OTLJ11N3	Strong	Biomarker	[18]
PAGR1	OTXR5PQ8	Strong	Biomarker	[6]
PCP4	OTM1XXYX	Strong	Biomarker	[19]
RNASE7	OTIXO0Z4	Strong	Biomarker	[20]
TNS3	OTPG2D8Z	Strong	Biomarker	[21]

References

• [1] Clinical pipeline report, company report or official report of R-Pharm.
• [2] ClinicalTrials.gov (NCT03137173) Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT03137173) Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections. U.S. National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of Nabriva Therapeutics.
• [5] ClinicalTrials.gov (NCT03964493) TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection (P2_ABSSSI). U.S. National Institutes of Health.
• [6] Functional and Proteomic Analysis of Streptococcus pyogenes Virulence Upon Loss of Its Native Cas9 Nuclease.Front Microbiol. 2019 Aug 22;10:1967. doi: 10.3389/fmicb.2019.01967. eCollection 2019.
• [7] Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection.Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):282-7. doi: 10.1073/pnas.0912373107. Epub 2009 Dec 4.
• [8] Genetic requirements for Staphylococcus aureus nitric oxide resistance and virulence.PLoS Pathog. 2018 Mar 19;14(3):e1006907. doi: 10.1371/journal.ppat.1006907. eCollection 2018 Mar.
• [9] Toxigenic profile of methicillin-sensitive and resistant Staphylococcus aureus isolated from special groups.Ann Clin Microbiol Antimicrob. 2016 Feb 16;15:9. doi: 10.1186/s12941-016-0125-5.
• [10] Designing an ultra-short antibacterial peptide with potent activity against Mupirocin-resistant MRSA.Chem Biol Drug Des. 2019 Jan;93(1):4-11. doi: 10.1111/cbdd.13377. Epub 2018 Sep 12.
• [11] Atopic dermatitis complicated by eczema herpeticum is associated with HLA B7 and reduced interferon--producing CD8+ T cells.Br J Dermatol. 2013 Sep;169(3):700-3. doi: 10.1111/bjd.12382.
• [12] Prevalence and Incidence of Upper Respiratory Tract Infection Events Are Elevated Prior to the Development of Rheumatoid Arthritis in First-Degree Relatives.Front Immunol. 2018 Nov 29;9:2771. doi: 10.3389/fimmu.2018.02771. eCollection 2018.
• [13] Characterization of a novel mouse model with genetic deletion of CD177.Protein Cell. 2015 Feb;6(2):117-26. doi: 10.1007/s13238-014-0109-1. Epub 2014 Oct 31.
• [14] Successful interferon-alpha 2b therapy for unremitting warts in a patient with DOCK8 deficiency.Clin Immunol. 2014 Jul;153(1):104-108. doi: 10.1016/j.clim.2014.04.005. Epub 2014 Apr 15.
• [15] ORF11 protein interacts with the ORF9 essential tegument protein in varicella-zoster virus infection.J Virol. 2013 May;87(9):5106-17. doi: 10.1128/JVI.00102-13. Epub 2013 Feb 20.
• [16] Cutaneous Deficiency of Filaggrin and STAT3 Exacerbates Vaccinia Disease In Vivo.PLoS One. 2017 Jan 12;12(1):e0170070. doi: 10.1371/journal.pone.0170070. eCollection 2017.
• [17] The Rho regulator Myosin IXb enables nonlymphoid tissue seeding of protective CD8(+) T cells.J Exp Med. 2018 Jul 2;215(7):1869-1890. doi: 10.1084/jem.20170896. Epub 2018 Jun 6.
• [18] Isolation, identification, and pathological effects of beach sand bacterial extract on human skin keratinocytes in vitro.PeerJ. 2018 Jan 12;6:e4245. doi: 10.7717/peerj.4245. eCollection 2018.
• [19] Novel antibiotics effective against gram-positive and -negative multi-resistant bacteria with limited resistance.PLoS Biol. 2019 Jul 9;17(7):e3000337. doi: 10.1371/journal.pbio.3000337. eCollection 2019 Jul.
• [20] The Antimicrobial and Immunomodulatory Function of RNase 7 in Skin.Front Immunol. 2019 Nov 5;10:2553. doi: 10.3389/fimmu.2019.02553. eCollection 2019.
• [21] Efflux pump-mediated resistance to antifungal compounds can be prevented by conjugation with triphenylphosphonium cation.Nat Commun. 2018 Nov 30;9(1):5102. doi: 10.1038/s41467-018-07633-9.